Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors 麻豆原创 Research Report 2023

Publication ID:

PB511232045

Publication Date:

November 1, 2023

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

SGLT2 is a member of the sodium-glucose cotransporter family which are sodium-dependent glucose transport proteins. SGLT2 is the major cotransporter involved in glucose reabsorption in the kidney.The growing global type-2 diabetes population promotes the growth of SGLT2 drugs.
The global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029.
Key manufacturers engaged in the Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors industry include Eli Lilly, Janssen Pharmaceuticals, Astellas, Boehringer Ingelheim, AstraZeneca, Bristol Myers Squibb and Kotobuki Pharmaceutical, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors market with multiple angles, which provides sufficient supports to readers鈥� strategy and decision making.
By Company
Eli Lilly
Janssen Pharmaceuticals
Astellas
Boehringer Ingelheim
AstraZeneca
Bristol Myers Squibb
Kotobuki Pharmaceutical
Segment by Type
Invokana (Canagliflozin)
Jardiance (Empagliflozin)
Farxiga/Forxiga (Dapagliflozin)
Suglat (Ipragliflozin)
Segment by Application
Hospital
Medical Research Institute
Other
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers鈥� Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers鈥� Outline
Chapter 7: Industry Chain, 麻豆原创 Channel and Customer Analysis
Chapter 8: 麻豆原创 Opportunities and Challenges
Chapter 9: 麻豆原创 Conclusions
Chapter 10: Research Methodology and Data Source

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors 麻豆原创 Overview
1.1 Product Overview and Scope of Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors
1.2 Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Segment by Type
1.2.1 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors 麻豆原创 Value Comparison by Type (2023-2029)
1.2.2 Invokana (Canagliflozin)
1.2.3 Jardiance (Empagliflozin)
1.2.4 Farxiga/Forxiga (Dapagliflozin)
1.2.5 Suglat (Ipragliflozin)
1.3 Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Segment by Application
1.3.1 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors 麻豆原创 Value by Application: (2023-2029)
1.3.2 Hospital
1.3.3 Medical Research Institute
1.3.4 Other
1.4 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors 麻豆原创 Size Estimates and Forecasts
1.4.1 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue 2018-2029
1.4.2 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales 2018-2029
1.4.3 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors 麻豆原创 Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors 麻豆原创 Competition by Manufacturers
2.1 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales 麻豆原创 Share by Manufacturers (2018-2023)
2.2 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue 麻豆原创 Share by Manufacturers (2018-2023)
2.3 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Average Price by Manufacturers (2018-2023)
2.4 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors, Product Type & Application
2.7 Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors 麻豆原创 Competitive Situation and Trends
2.7.1 Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors 麻豆原创 Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Players 麻豆原创 Share by Revenue
2.7.3 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors 麻豆原创 Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Retrospective 麻豆原创 Scenario by Region
3.1 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors 麻豆原创 Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales by Region: 2018-2029
3.2.1 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales by Region: 2018-2023
3.2.2 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales by Region: 2024-2029
3.3 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue by Region: 2018-2029
3.3.1 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue by Region: 2018-2023
3.3.2 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue by Region: 2024-2029
3.4 North America Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors 麻豆原创 Facts & Figures by Country
3.4.1 North America Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales by Country (2018-2029)
3.4.3 North America Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue by Country (2018-2029)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors 麻豆原创 Facts & Figures by Country
3.5.1 Europe Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales by Country (2018-2029)
3.5.3 Europe Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors 麻豆原创 Facts & Figures by Country
3.6.1 Asia Pacific Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales by Country (2018-2029)
3.6.3 Asia Pacific Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors 麻豆原创 Facts & Figures by Country
3.7.1 Latin America Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales by Country (2018-2029)
3.7.3 Latin America Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors 麻豆原创 Facts & Figures by Country
3.8.1 Middle East and Africa Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales by Country (2018-2029)
3.8.3 Middle East and Africa Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales by Type (2018-2029)
4.1.1 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales by Type (2018-2023)
4.1.2 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales by Type (2024-2029)
4.1.3 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales 麻豆原创 Share by Type (2018-2029)
4.2 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue by Type (2018-2029)
4.2.1 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue by Type (2018-2023)
4.2.2 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue by Type (2024-2029)
4.2.3 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue 麻豆原创 Share by Type (2018-2029)
4.3 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Price by Type (2018-2029)
5 Segment by Application
5.1 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales by Application (2018-2029)
5.1.1 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales by Application (2018-2023)
5.1.2 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales by Application (2024-2029)
5.1.3 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales 麻豆原创 Share by Application (2018-2029)
5.2 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue by Application (2018-2029)
5.2.1 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue by Application (2018-2023)
5.2.2 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue by Application (2024-2029)
5.2.3 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue 麻豆原创 Share by Application (2018-2029)
5.3 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Eli Lilly
6.1.1 Eli Lilly Corporation Information
6.1.2 Eli Lilly Description and Business Overview
6.1.3 Eli Lilly Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Eli Lilly Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Product Portfolio
6.1.5 Eli Lilly Recent Developments/Updates
6.2 Janssen Pharmaceuticals
6.2.1 Janssen Pharmaceuticals Corporation Information
6.2.2 Janssen Pharmaceuticals Description and Business Overview
6.2.3 Janssen Pharmaceuticals Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Janssen Pharmaceuticals Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Product Portfolio
6.2.5 Janssen Pharmaceuticals Recent Developments/Updates
6.3 Astellas
6.3.1 Astellas Corporation Information
6.3.2 Astellas Description and Business Overview
6.3.3 Astellas Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Astellas Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Product Portfolio
6.3.5 Astellas Recent Developments/Updates
6.4 Boehringer Ingelheim
6.4.1 Boehringer Ingelheim Corporation Information
6.4.2 Boehringer Ingelheim Description and Business Overview
6.4.3 Boehringer Ingelheim Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Boehringer Ingelheim Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Product Portfolio
6.4.5 Boehringer Ingelheim Recent Developments/Updates
6.5 AstraZeneca
6.5.1 AstraZeneca Corporation Information
6.5.2 AstraZeneca Description and Business Overview
6.5.3 AstraZeneca Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales, Revenue and Gross Margin (2018-2023)
6.5.4 AstraZeneca Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Product Portfolio
6.5.5 AstraZeneca Recent Developments/Updates
6.6 Bristol Myers Squibb
6.6.1 Bristol Myers Squibb Corporation Information
6.6.2 Bristol Myers Squibb Description and Business Overview
6.6.3 Bristol Myers Squibb Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Bristol Myers Squibb Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Product Portfolio
6.6.5 Bristol Myers Squibb Recent Developments/Updates
6.7 Kotobuki Pharmaceutical
6.6.1 Kotobuki Pharmaceutical Corporation Information
6.6.2 Kotobuki Pharmaceutical Description and Business Overview
6.6.3 Kotobuki Pharmaceutical Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Kotobuki Pharmaceutical Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Product Portfolio
6.7.5 Kotobuki Pharmaceutical Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Industry Chain Analysis
7.2 Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Production Mode & Process
7.4 Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales and 麻豆原创ing
7.4.1 Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales Channels
7.4.2 Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Distributors
7.5 Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Customers
8 Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors 麻豆原创 Dynamics
8.1 Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Industry Trends
8.2 Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors 麻豆原创 Drivers
8.3 Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors 麻豆原创 Challenges
8.4 Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors 麻豆原创 Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 麻豆原创 Size Estimation
10.1.3 麻豆原创 Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Companies Mentioned:

Eli Lilly
Janssen Pharmaceuticals
Astellas
Boehringer Ingelheim
AstraZeneca
Bristol Myers Squibb
Kotobuki Pharmaceutical

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.